TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06941142: An Ib/III Study to Evaluate the Safety and Efficacy of Sirolimus（Albumin-bound）in Combination With Palbociclib and Fulvestrant in Patients With Advanced HR- Positive, HER2- Negative Breast Cancer

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 382 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06941142 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06941142 Rescue Dossier →